Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7067)
All Articles published online
|
Publishing Process of This Article
|
Feb 28, 2015 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Lv ZF, Wang FC, Zheng HL, Wang B, Xie Y, Zhou XJ, Lv NH. Meta-analysis: Is combination of tetracycline and amoxicillin suitable for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i8/2522.htm |
| Number | Citing Articles |
| 1 |
Yong Xie, Yi Hu, Yin Zhu, Hong Wang, Qi‐Zhi Wang, Yan‐Qing Li, Jiang‐Bin Wang, Zhen‐Yu Zhang, De‐Kui Zhang, Xiao‐Wei Liu, Nong‐Hua Lu. Colloidal bismuth pectin‐containing quadruple therapy as the first‐line treatment of Helicobacter pylori infection: A multicenter, randomized, double‐blind, non‐inferiority clinical trial. Helicobacter 2023; 28(3) doi: 10.1111/hel.12978
|
| 2 |
Yiying Pei, Daphne Ang, Andrew Boon Eu Kwek, Tiing Leong Ang. Changing profile of Helicobacter pylori primary antibiotic resistance in Singapore over two decades. Journal of Digestive Diseases 2022; 23(5-6): 295 doi: 10.1111/1751-2980.13115
|
| 3 |
Ju Yup Lee, Nayoung Kim, Kyung Sik Park, Hyun Jin Kim, Seon Mee Park, Gwang Ho Baik, Ki-Nam Shim, Jung Hwan Oh, Suck Chei Choi, Sung Eun Kim, Won Hee Kim, Seon-Young Park, Gwang Ha Kim, Bong Eun Lee, Yunju Jo, Su Jin Hong. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial. BMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0490-8
|
| 4 |
Wen Zhong Liu, Yong Xie, Hong Lu, Hong Cheng, Zhi Rong Zeng, Li Ya Zhou, Ye Chen, Jiang Bin Wang, Yi Qi Du, Nong Hua Lu. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018; 23(2) doi: 10.1111/hel.12475
|
| 5 |
Lei Gu, Shenglan Li, Ying He, Yi Chen, Yanzhi Jiang, Yu Peng, Xiaowei Liu, Huixiang Yang. Bismuth, rabeprazole, amoxicillin, and doxycycline as first‐line Helicobacter pylori therapy in clinical practice: A pilot study. Helicobacter 2019; 24(4) doi: 10.1111/hel.12594
|
| 6 |
Yingchao Sun, Mengjia Zhu, Lei Yue, Weiling Hu. Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy. Journal of Clinical Medicine 2022; 11(23): 7040 doi: 10.3390/jcm11237040
|
| 7 |
Song-Wei Wang, Fang-Jung Yu, Fu-Chen Kuo, Jiunn-Wei Wang, Yao-Kuang Wang, Yi-Hsun Chen, Wen-Hung Hsu, Chung-Jung Liu, Deng-Chyang Wu, Chao-Hung Kuo. Rescue therapy for refractoryHelicobacter pyloriinfection: current status and future concepts. Therapeutic Advances in Gastroenterology 2023; 16: 175628482311709 doi: 10.1177/17562848231170941
|
| 8 |
Blas José Gómez Rodríguez, Luisa Castro Laria, Federico Argüelles Arias, Cristina Castro Márquez, Ángel Caunedo Álvarez, Manuel Romero Gómez. A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients. Revista Española de Enfermedades Digestivas 2017; 109 doi: 10.17235/reed.2017.4809/2016
|
| 9 |
Ester di Giacomo, Enrico Biagi, Fabrizia Colmegna, Flora Aspesi, Antonios Dakanalis, Maria Fotiadou, Massimo Clerici. Progresses about the Interplay among Clarithromycin, Immune and Central Nervous Systems. Journal of Neuroimmune Pharmacology 2017; 12(4): 566 doi: 10.1007/s11481-017-9758-1
|
| 10 |
Jingshu Chi, Canxia Xu, Xiaoming Liu, Hao Wu, Xiaoran Xie, Peng Liu, Huan Li, Guiying Zhang, Meihua Xu, Chaomin Li, Chunlian Wang, Fengqian Song, Ming Yang, Jie Wu. A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating Helicobacter pylori-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China. Pathogens 2022; 11(12): 1549 doi: 10.3390/pathogens11121549
|
| 11 |
Ki-Young Lee, Bong-Jin Lee. Solution NMR studies onHelicobacter pyloriproteins for antibiotic target discovery. Expert Opinion on Drug Discovery 2016; 11(7): 681 doi: 10.1080/17460441.2016.1189411
|
| 12 |
Maliheh Safavi, Reyhaneh Sabourian, Alireza Foroumadi. Treatment of <i>Helicobacter pylori</i> infection: Current and future insights. World Journal of Clinical Cases 2016; 4(1): 5-19 doi: 10.12998/wjcc.v4.i1.5
|
| 13 |
Elena Pérez-Arellano, María Isabel Rodriguez-Garcia, Ana Belen Galera Rodenas, Emilio de la Morena-Madrigal. Erradicación de la infección por Helicobacter pylori con una nueva terapia cuádruple basada en bismuto en la práctica clínica. Gastroenterología y Hepatología 2018; 41(3): 145 doi: 10.1016/j.gastrohep.2017.08.005
|
| 14 |
Kanishka Uthansingh, Ratna Kumari, Girish Kumar Pati, Manas Kumar Behera, Mahesh Chandra Sahu, Jimmy Narayan, Swarup Kumar Patnaik, Pradeep Mallick, Manoj Kumar Sahu. Molecular Docking of Anti Helicobacter pylori Antibiotics and Proton Pump Inhibitor: A Single Center Survey. Journal of Pure and Applied Microbiology 2021; 15(4): 2103 doi: 10.22207/JPAM.15.4.33
|
| 15 |
Yiqiao Xin, Jan Manson, Lindsay Govan, Robin Harbour, Jenny Bennison, Eleanor Watson, Olivia Wu. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0491-7
|
| 16 |
Bingxue Dong, Kunn Hadinoto. Assessing the impact of counterion types on the sustained release characteristics of high-payload drug-ion complex: A case study on tetracycline hydrochloride. European Journal of Pharmaceutical Sciences 2021; 161: 105787 doi: 10.1016/j.ejps.2021.105787
|
| 17 |
Junxian Wang, Yuping Cao, Wei He, Xiaoping Li. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine 2021; 100(51): e28323 doi: 10.1097/MD.0000000000028323
|
| 18 |
Tiankuo Yang, Renwei Hu, Xiaoqiong Tang, Yalin Shen, Alfred Tay, Xuenan Pi, Gang Wang, Aleksandra W Debowski, Keith A Stubbs, Mohammed Benghezal, Barry J Marshall, Hong Li, Hong Tang. Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections. Precision Clinical Medicine 2020; 3(2): 127 doi: 10.1093/pcmedi/pbaa010
|
| 19 |
Elena Pérez-Arellano, María Isabel Rodriguez-Garcia, Ana Belen Galera Rodenas, Emilio de la Morena-Madrigal. Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice. Gastroenterología y Hepatología (English Edition) 2018; 41(3): 145 doi: 10.1016/j.gastre.2018.03.004
|
| 20 |
Jun-Hyung Cho, So-Young Jin. Current guidelines for <i>Helicobacter pylori </i>treatment in East Asia 2022: Differences among China, Japan, and South Korea. World Journal of Clinical Cases 2022; 10(19): 6349-6359 doi: 10.12998/wjcc.v10.i19.6349
|